Peter Salzmann, Immunovant CEO

Im­muno­vant un­veils pos­i­tive ear­ly da­ta for PhII Graves' dis­ease drug

Im­muno­vant’s drug for Graves’ dis­ease showed a re­sponse rate that ex­ceed­ed 50% in an ini­tial co­hort of pa­tients in an on­go­ing 24-week Phase II clin­i­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.